An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

NCT01848340 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-associated Lipodystrophy Syndrome

Interventions

DRUG: GSK1265744B (sodium salt) containing 14C-GSK1265744B
DRUG: 150 mg GSK1265744B
DRUG: Placebo

Sponsor

ViiV Healthcare

Collaborators

[object Object]